Activity OverviewThe Pediatric Rheumatology Course 2023 features key updates on a wide range of pediatric rheumatology diseases including juvenile dermatomyositis, JIA, chronic nonbacterial osteomyelitis (CNO), Kawasaki disease, and mental health in children with rheumatic disease. The activity is well-suited for anyone who needs an update in the field of pediatric rheumatology. The activity consists of recorded sessions from several ACR 2023 live meetings: Pediatric Rheumatology Symposium, Education Exchange, and ACR Convergence. There are six lectures that range in duration from 30 minutes to 2 hours and include a recorded Q&A session.Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. Target AudiencePrimary care providers, rheumatologists, and rheumatology interprofessionals.Learning ObjectivesUpon completion of this activity, participants should be able to:Review seminal work on calcinosis developmentAnalyze the strengths and limitations of different assessments of calcinosis, including imaging techniquesReview the evidence to support treatment decisions for calcinosisList the multiple ways in which chronic nonbacterial osteomyelitis (CNO) may present in current pediatric rheumatology practiceDescribe the role of whole body MRI in the detection and monitoring of CNO, relative to other imaging modalitiesDescribe the medications currently used for CNO and the available evidence supporting their useDiscuss the management of refractory non-systemic juvenile idiopathic arthritis (JIA) and uveitisDiscuss withdrawal of DMARDs for well-controlled, non-systemic JIA and uveitis, including timing, strategy, monitoring, and approach to flareReview the 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki DiseaseRecognize mental health impact, current care practices, and gapsIdentify clinical practice change for optimized mental healthcareIdentify factors contributing to the relationship between rheumatologic disease and mental health in affected youthReview recent advances in imaging of Takayasu arteritis (TAK) and how/when to use information from serial imaging to tailor treatmentsDemonstrate which biologics have been studied in TAK and how this can be applied to the pediatric populationReview advances in vessel wall imaging in childhood primary angiitis of the central nervous system (cPACNS)Discuss treatment protocols in cPACNSCE & MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.   AMA Designation Statement The American College of Rheumatology designates this enduring material for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by August 29, 2027, at 11:59 PM ET. MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.  After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.   MOC Recognition Statement: American Board of Pediatrics (ABP) Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 6.75 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit. After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABP diplomates to the ABP diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABP Physician Portals. Please allow at least 48 hours for points to display in the portal.MOC points must be claimed by August 29, 2027, at 11:59 PM ET. Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. Nature of Financial Relationships All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify details None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.  Faculty The following authors have no relevant financial relationship(s) with ineligible companies to disclose. Hedrich, Christian, MD, PhD - Novartis, 2 (Terminated, August 31, 2021)Ferguson, Polly, MD - No financial relationships with ineligible companies to discloseDoria, Andrea, MD, PhD, MSc, MBA - Baxalta-Shire, 5 (Ongoing); Novo Nordisk, 5 (Ongoing); Terry Fox Foundation, 5 (Ongoing)Lood, Christian, PhD - No financial relationships with ineligible companies to discloseSchiffenbauer, Adam, MD - AstraZeneca, 5 (Ongoing); Hope Pharmaceuticals, 5 (Ongoing)Pilkington, Clarissa, MBBS, BSc, FRCPC, FRCP - No financial relationships with ineligible companies to discloseMelissa Mannion, MD - No financial relationships with ineligible companies to discloseJoost Swart, MD, PhD - No financial relationships with ineligible companies to discloseAshley M. Cooper, MD - No financial relationships with ineligible companies to discloseMark Gorelik, MD - No financial relationships with ineligible companies to discloseKnight, Andrea, MD, MSCE - Pfizer, 6 (Ongoing)Vora, Sheetal, MD, MS - No financial relationships with ineligible companies to discloseLeever, Alana, PhD - No financial relationships with ineligible companies to discloseEdison, Suzanne, MA, MFA - No financial relationships with ineligible companies to discloseSusanne (Susa) Benseler, MD, PhD, FRCPC -  No financial relationships with ineligible companies to discloseOzen, Seza, MD, MSc - No financial relationships with ineligible companies to discloseKaitlin Quinn, MD;MHS - No financial relationships with ineligible companies to disclose   Planning Team Members The following editors and reviewers have no relevant financial relationship(s) with ineligible companies to disclose. Adena Batterman, LCSW, MSWBelina Yi, D.O.Annelle Reed, MSN, CPNPKai Sun, MD, MSDawn Wahezi, MD, MSRebecca Manno, MD, MHSMaura Daly Iversen, PT, DPT, SD, MPH, FNAP, FAPTASusan FarrowLawrence CunninghamCarlos Ferreira, MASharon Ross   The following editors and reviewers have relevant financial relationship(s) with ineligible companies to disclose.Kaveh Ardalan, MD, MS – Cabaletta Bio, Inc. 1; Cure JM Foundation5Susan Shenoi, MBBS, MS, RhMSUS – Pfizer2; Cabaletta Bio, Inc2; Novartis2; Amgen2Lesley Ann Saketkoo, MD, MPH - Argenx1,5; Atyr1,5; Boehringer Ingelheim1,5; Horizon1,5; Janssen1,5; Kadmon1,5; Kinevant1,5; Kyverna1,5; Mallinckrodt1,5; Novartis1,5; UCB1,5*All of the relevant financial relationships listed for these individuals have been mitigated.Acknowledgement of Commercial SupportNo commercial support was provided for this activity.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewRheum2Learn 2.0 is case-based fundamental clinical rheumatology education for residents. Each interactive activity includes three patient cases that focus on the care and assessment of individuals with rheumatologic diseases.In this activity, learn how to examine, diagnose, and implement a pediatric patient-centered approach for three children with rheumatic conditions. The conditions included are juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM), and Kawasaki disease (KD). Rheum2Learn SeriesThis activity is part of a series. See all activities in the series below.Rheum2Learn 2.0: Crystalline ArthritisRheum2Learn 2.0: Infectious ArthritisRheum2Learn 2.0: Inflammatory MyopathiesRheum2Learn 2.0: Musculoskeletal DisordersRheum2Learn 2.0: Musculoskeletal ExaminationRheum2Learn 2.0: OsteoporosisRheum2Learn 2.0: OsteoarthritisRheum2Learn 2.0: Pediatric RheumatologyRheum2Learn 2.0: Rheumatic Manifestations of Systemic DiseaseRheum2Learn 2.0: Rheumatoid ArthritisRheum2Learn 2.0: SpondyloarthritisRheum2Learn 2.0: Sjögren’s DiseaseRheum2Learn 2.0: Systemic Lupus ErythematosusRheum2Learn 2.0: Systemic SclerosisRheum2Learn 2.0: Systemic VasculitisRegistration is complimentary.Target AudienceResidents in training who may provide care for pediatric patients with rheumatic diagnoses in primary care, inpatient, critical care, and other clinical contexts.The activity may also be of interest to medical students, fellows in training, advanced practice providers, practicing physicians, and other health care professionals who seek to strengthen their clinical knowledge of rheumatic diseases. Learning ObjectivesUpon completion of this activity, participants should be able to:Formulate a differential diagnosis for a child with joint painExplain the role of laboratory tests in diagnosing and managing juvenile idiopathic arthritis (JIA)Recognize the major distinguishing features of the 7 types of JIAIndicate the complications associated with JIAOutline general management strategies for JIAIdentify common cutaneous findings associated with juvenile dermatomyositis (JDM)Describe physical exam maneuvers used to assess for weakness in a child with suspected myositis Compare and contrast features of inflammatory and non-inflammatory myopathiesRecognize the common and potentially life-threatening complications associated with JDMOutline treatment strategies for children with JDMOutline the clinical features and diagnostic criteria for Kawasaki Disease (KD) Formulate a differential diagnosis for a child with suspected KDDescribe risk factors for the major complications of KDPropose a treatment regimen for children with suspected KDCE & MOC InformationThis activity is not eligible for CME/MOC.Acknowledgement of Commercial SupportThe project was supported by grant number 1 NU58DP006908-01-00 – Component A: Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.